BRAF and colorectal cancer: These findings reinforce the established role of anti-EGFR/BRAF based regimens in advanced BRAF-mutated colorectal cancer, challenging the traditional first line standard of care, doublet or triplet chemotherapy combined with anti-VEGF regimens, and further validating the clinical utility of anti-EGFR/BRAF strategies as later line therapy for this molecularly defined population.